Physician profile
Matthew E Schaefer
NPI 1346205648
$46,121.38
in general payments reported to CMS, 2019-2025
41 companies · $969 in 2025
The $969 reported for 2025 was more than what 77% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $245 · 2021: $12K · 2022: $2,230 · 2023: $4,174 · 2024: $1,047 · 2025: $969.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,260 · Acquisitions: $2,899 · Education: $30.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,259.80 |
| Acquisitions | $2,899.43 |
| Education | $30.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $24,978.00 | 2019 | |
| Medtronic, INC. | $15,582.13 | 2021-2023 | Ellipsys Vascular Access System |
| Astrazeneca Pharmaceuticals Lp | $943.61 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $597.25 | 2019-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $497.71 | 2020-2023 | Acthar |
| Daiichi Sankyo INC. | $468.51 | 2019-2025 | Injectafer |
| Aurinia Pharma U.S., INC. | $379.87 | 2022-2024 | Lupkynis |
| Vifor Pharma, INC. | $271.93 | 2020-2024 | Veltassa, Korsuva |
| Mallinckrodt Enterprises LLC | $222.04 | 2019 | |
| Travere Therapeutics, INC. | $219.88 | 2019-2025 | |
| Glaxosmithkline, LLC. | $182.99 | 2022-2025 | Benlysta, Shingrix, Arexvy |
| Calliditas Therapeutics US INC. | $173.21 | 2022-2025 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $163.72 | 2021-2025 | Rayaldee |
| Amgen INC. | $148.83 | 2019-2025 | Tavneos, Krystexxa |
| Horizon Therapeutics Plc | $138.97 | 2019-2023 | Krystexxa |
Show all 39 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Schaefer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.